Insights

Access to advanced cell and gene therapies has been limited by their high cost. We've been looking at how AI can play a role in reducing the cost of manufacture of cell and gene therapies and hence make these treatments available to more patients.

The emergence of cell-based therapy's is one of the most important human stories of our time. Read our synthetic vision of affordable and accessible cell therapy for all...

Decarbonising aviation is a herculean task. Even an aircraft as fuel efficient as Boeing’s 787 Dreamliner uses 30 tonnes of kerosene to fly across the Atlantic. Batteries can’t be expected to achieve the power to weight ratio needed to replace this fuel. For all the interest in green hydrogen and related synthetic fuels it will be decades before a truly zero-carbon airliner can be expected to be carrying passengers. 

From almost three years of pandemic restrictions to a three-day biology bonanza. Senior Biomedical Engineer Ellen Simmons gets back on the live conference trail with a visit to Built With Biology, formerly SynBioBeta. Here she shares her experiences – and enthusiasm for helping to drive the biotech ecosystem forwards… 

Our brand relaunch has landed just as we ramp up our commitment to The Engine, the ambitious venture capital firm spun out of MIT to support ‘Tough Tech’ companies and solve key challenges in climate change, human health and advanced systems. 

Fresh from an in-person visit to BioData World Conference 2021, Andrew Goulter discusses the role big pharma is playing in unlocking a complex new healthcare ecosystem. His hope? That effective data sharing and democratised access will deliver advantages for healthcare professionals and patients alike… 
 

Cambridge Consultants' Mike Dunkley, SVP, Bioinnovation, hosts a panel with industry leaders from Kytopen, CATALOG and Galy to explore transformative technologies for cell transfection, lab-grown cotton and DNA data storage. 

Cell and gene therapy is hailed as the future of 21st century medicine but is currently too expensive to be widely used. As a principal scientist in bioinnovation, I’ve been part of a team addressing this issue in an ambitious project with exciting potential…

PureSentry: Can real-time contamination detection transform cell therapy manufacture? 

This paper explains how ‘turning trash into cash’ provides opportunity for companies to gain first-mover advantage in several fields. With a clear, problem/solution approach, it outlines a method that be considered simply as a way to capture carbon – but is more likely to yield benefits in the creation of valuable bio-derived compounds.

Luis Diaz-Santana, Head of Ophthalmology at Cambridge Consultants, presented at OIS European Showcase virtual conference. Watch his presentation to hear his thoughts on if Europe really is an innovation powerhouse in ophthalmology.

The ambition to reduce or eliminate single-use plastics from the world’s supply chains is of course as laudable as it is essential. I’m proud to be part of a team of colleagues dedicated to doing something about it – by creating a guide that is helping innovators switch to alternatives.